BOSTON (Reuters) - U.S. regulators said on Wednesday they have found no link between oral bisphosphonate osteoporosis medications such as Merck & Co Inc's Fosamax and certain thigh bone fractures. The Food and Drug Administration issued its statement following the publication of case reports of atypical subtrochanteric femur fractures -- or fractures in the bone just below the hip joint ...

A promising Alzheimer's disease drug Pfizer Inc. and a partner are developing failed to work in a late-stage study, a startling disappointment after the potential blockbuster kept symptoms from worsening for a year in a prior test. Pfizer and partner Medivation Inc. said Wednesday ...

DRUG DISAPPOINTMENT: After strong results in a midstage study, an Alzheimer's drug Pfizer Inc. is developing with a partner unexpectedly failed to work in a late-stage patient test. WHAT'S NEXT: Scientists at Pfizer and Medivation Inc. will analyze the data to try ...

Shares of Medivation Inc. plunged Wednesday after the failure of Dimebon, an Alzheimer's drug the company is developing with Pfizer Inc. Medivation stock lost about two-thirds of its value and fell to an annual low Wednesday morning. Before the market opened, Medivation and Pfizer said ...